Romiplostim (AMG-531)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Conditions
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Trial Timeline
Feb 1, 2006 → Nov 1, 2006
NCT ID
NCT00305435About Romiplostim (AMG-531)
Romiplostim (AMG-531) is a phase 2 stage product being developed by Kyowa Kirin for Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT00305435. Target conditions include Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00305435 | Phase 2 | Completed |
Competing Products
20 competing products in Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)